Niosomal Drug Delivery System used in Tuberculosis

  • Oma Shanker Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India
  • Arsh Chanana Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India
  • Pooja Gupta Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India
  • Aditya Narayan Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India
  • Yukta R. Kulkarni Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India
  • Akhilesh Patel Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India
  • Ujwal havelikar Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India
  • Bhabesh Mahato Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India
  • Ravindra Pal Singh Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India
  • Himmat Singh Chawra Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India
  • Anurag Mishra Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

Abstract

Niosomes are artificially manufactured vesicles made of Cholesterol and Non-ionic surfactant. Their capacity to encapsulate a broad variety of pharmaceuticals and shield them from deterioration has piqued interest in drug delivery. Niosomes have demonstrated a possible use in the administration of anti-tuberculosis medications. Worldwide, tuberculosis is a serious public health concern. Even with advances in science and technology, tuberculosis remains a persistent problem.Niosomes can encapsulate anti-TB drugs, protecting them from enzymatic degradation and allowing for sustained release. Research in this field is on-going, with scientists working on optimizing niosomal formulations for tuberculosis treatment. It's important to consult current scientific literature for the latest advancements. Some anti-tubercular drugs face challenges in terms of absorption and bioavailability. Niosomal delivery systems can help address these issues. While niosomal drug delivery systems show promise, it's crucial to note that they are still an area of active research and specific formulations and protocols may vary. Patients should always consult with their healthcare providers for the most appropriate and up-to-date treatment options for tuberculosis. Niosomes can encapsulate both hydrophilic and lipophilic drugs, offering advantages such as increased drug stability, prolonged circulation time, controlled release, and targeted delivery. They have applications in various fields including pharmaceuticals, cosmetics, and agriculture.


Keywords: Tuberculosis, Niosomes, Drug delivery system

Keywords: Tuberculosis, Niosomes, Drug delivery system

Downloads

Download data is not yet available.

Author Biographies

Oma Shanker, Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

Arsh Chanana, Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

Pooja Gupta, Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

Aditya Narayan, Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

Yukta R. Kulkarni, Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

Akhilesh Patel, Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

Ujwal havelikar, Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

Bhabesh Mahato, Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

Ravindra Pal Singh, Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

Himmat Singh Chawra, Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

Anurag Mishra, Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University Rajasthan, India

References

1) Sangboonruang S, Semakul N, Suriyaprom S, Kitidee K, Khantipongse J, Intorasoot S, Tharinjaroen CS, Wattananandkul U, Butr-Indr B, Phunpae P, Tragoolpua K. Nano-Delivery System of Ethanolic Extract of Propolis Targeting Mycobacterium tuberculosis via Aptamer-Modified-Niosomes. Nanomaterials. 2023 Jan 8;13(2):269. https://doi.org/10.3390/nano13020269 PMid:36678022 PMCid:PMC9861461
2) Grotz E, Tateosian N, Amiano N, Cagel M, Bernabeu E, Chiappetta DA, Moretton MA. Nanotechnology in tuberculosis: state of the art and the challenges ahead. Pharmaceutical Research. 2018 Nov;35:1-22. https://doi.org/10.1007/s11095-018-2497-z PMid:30238168
3) Haddadian A, Robattorki FF, Dibah H, Soheili A, Ghanbarzadeh E, Sartipnia N, Hajrasouliha S, Pasban K, Andalibi R, Ch. MH, Azari A. Niosomes-loaded selenium nanoparticles as a new approach for enhanced antibacterial, anti-biofilm, and anticancer activities. Scientific reports. 2022 Dec 19;12(1):21938. https://doi.org/10.1038/s41598-022-26400-x PMid:36536030 PMCid:PMC9763330
4) Abdelbary A, Essam T, Abd El-Salam RM, AlyKassem AA. Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin (antifungal). Drug Dev Ind Pharm. 2011;37:149-508. https://doi.org/10.3109/03639045.2011.587431 PMid:21707323
5) Suárez I, Fünger SM, Kröger S, Rademacher J, Fätkenheuer G, Rybniker J, "The Diagnosis and Treatment of Tuberculosis" DtschArzteblInt, 2019; 116(43):729-735. https://doi.org/10.3238/arztebl.2019.0729 PMid:31755407
6) Peña DA, Rosetta AI, Hernández Del Pino RE, Amiano NO, Pasquinelli V, Pellegrini JM, et al. Mycobacterium tuberculosis dormancy antigen differentiates latently infected Bacillus Chalmette-Guerin vaccinated individuals. Biomedicine. 2015;2(8):882-8. https://doi.org/10.1016/j.ebiom.2015.05.026 PMid:26425695 PMCid:PMC4563115
7) Gogna A, Pradhan GR, Sinha RS, Gupta B, "Tuberculosis presenting as deep vein thrombosis" Postgrad Med J, 1999; 75(880):104-105. https://doi.org/10.1136/pgmj.75.880.104 https://doi.org/10.1136/pgmj.75.880.104 PMid:10448473 PMCid:PMC1741133
8) Porcel JM, Leung CC, Restrepo MI, Lee P. Year in review 2011: respiratory infections, tuberculosis, pleural diseases, bronchoscopic intervention and imaging. Respirology. 2012;17(3):573-82. https://doi.org/10.1111/j.1440-1843.2012.02128.x PMid:22248294 PMCid:PMC4066650
9) Al-Tawfiq JA, "Multifocal systemic tuberculosis: the many faces of an old nemesis" Med SciMonit, 2007; 13(4):56-60
10) Maiolini, M.; Gause, S.; Taylor, J.; Steakin, T.; Shipp, G.; Lamichhane, P.; Deshmukh, B.; Shinde, V.; Bishayee, A.; Deshmukh, R.R. The war against tuberculosis: A review of natural compounds and their derivatives. Molecules 2020, 25, 3011. https://doi.org/10.3390/molecules25133011 PMid:32630150 PMCid:PMC7412169
11) Bouzeyen, R.; Javid, B. Therapeutic vaccines for tuberculosis: An overview. Front. Immunol. 2022, 13, 878471. https://doi.org/10.3389/fimmu.2022.878471 PMid:35812462 PMCid:PMC9263712
12) Allue-Guardia, A.; Garcia, J.I.; Torrelles, J.B. Evolution of drug-resistant Mycobacterium tuberculosis strains and their adaptation to the human lung environment. Front. Microbiol. 2021, 12, 612675. https://doi.org/10.3389/fmicb.2021.612675 PMid:33613483 PMCid:PMC7889510
13) Huang, Z.; Klodzinska, S.N.; Wan, F.; Nielsen, H.M. Nanoparticle-mediated pulmonary drug delivery: State of the art towards efficient treatment of recalcitrant respiratory tract bacterial infections. Drug Deliv. Transl. Res. 2021, 11, 1634-1654. https://doi.org/10.1007/s13346-021-00954-1 PMid:33694082 PMCid:PMC7945609
14) Zabaiou, N.; Fouache, A.; Trousson, A.; Baron, S.; Zellagui, A.; Lahouel, M.; Lobaccaro, J.A. Biological properties of propolis extracts: Something new from an ancient product. Chem. Phys. Lipids 2017, 207, 214-222. https://doi.org/10.1016/j.chemphyslip.2017.04.005 PMid:28411017
15) Sforcin, J.M. Biological properties and therapeutic applications of propolis. Phytother. Res. 2016, 30, 894-905. https://doi.org/10.1002/ptr.5605 PMid:26988443
16) Anjum, S.I.; Ullah, A.; Khan, K.A.; Attaullah, M.; Khan, H.; Ali, H.; Bashir, M.A.; Tahir, M.; Ansari, M.J.; Ghramh, H.A.; et al. Composition and functional properties of propolis (bee glue): A review. Saudi J. Biol. Sci. 2019, 26, 1695-1703. https://doi.org/10.1016/j.sjbs.2018.08.013 PMid:31762646 PMCid:PMC6864204
17) Sforcin, J.M.; Bankova, V. Propolis: Is there a potential for the development of new drugs? J. Ethnopharmacol. 2011, 133, 253-260. https://doi.org/10.1016/j.jep.2010.10.032 PMid:20970490
18) Pando, D.; Gutiérrez, G.; Coca, J.; Pazos, C. Preparation and characterization of niosomes containing resveratrol. J. Food Eng. 2013, 117, 227-234. https://doi.org/10.1016/j.jfoodeng.2013.02.020
19) Lo, C.T.; Jahn, A.; Locascio, L.E.; Vreeland, W.N. Controlled self-assembly of monodisperse niosomes by microfluidic hydrodynamic focusing. Langmuir ACS J. Surf. Colloids 2010, 26, 8559-8566. https://doi.org/10.1021/la904616s PMid:20146467
20) Obeid, M.A.; Elburi, A.; Young, L.C.; Mullen, A.B.; Tate, R.J.; Ferro, V.A. Formulation of non-ionic surfactant vesicles (NISV) prepared by microfluidics for therapeutic delivery of siRNA into cancer cells. Mol. Pharm. 2017, 14, 2450-2458. https://doi.org/10.1021/acs.molpharmaceut.7b00352 PMid:28570823
21) Obeid, M.A.; Khadra, I.; Mullen, A.B.; Tate, R.J.; Ferro, V.A. the effects of hydration media on the characteristics of non-ionic surfactant vesicles (NISV) prepared by microfluidics. Int. J. Pharm. 2017, 516, 52-60. https://doi.org/10.1016/j.ijpharm.2016.11.015 PMid:27836752
22) Pardakhty, A.; Varshosaz, J.; Rouholamini, A. In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int. J. Pharm. 2007, 328, 130-141. https://doi.org/10.1016/j.ijpharm.2006.08.002 PMid:16997517
23) Bhagyashree, K.; Seema, T.; Ankur, G.; Dada, P.; Deepa, P.; Ismail, M.; Basavan, D. Development and biological evaluation of Gymnema sylvestre extract-loaded nonionic surfactant-based niosomes. Nanomedicine 2013, 8, 1295-1305. https://doi.org/10.2217/nnm.12.162 PMid:23259778
24) Zarei, M.; Norouzian, D.; Honarvar, B.; Mohammadi, M.; Shamabadi, H.E.; Akbarzadeh, A. Paclitaxel Loaded Niosome Nanoparticle Formulation Prepared via Reverse Phase Evaporation Method: An in vitro Evaluation. Pak. J. Biol. Sci. 2013, 16, 295-298. https://doi.org/10.3923/pjbs.2013.295.298 PMid:24498794
25) Jain, S.; Vyas, S.P. Mannosylated niosomes as adjuvant-carrier system for oral mucosal immunization. J. Liposome Res. 2006, 16, 331-345. https://doi.org/10.1080/08982100600992302 PMid:17162576
26) Shegokar, R.; Al, S.L.; Mitri, K. Present status of nanoparticle research for treatment of tuberculosis. J. Pharm. Pharm. Sci. 2011, 14, 100-116. https://doi.org/10.18433/J3M59P PMid:21501557
27) Bragagni, M.; Mennini, N.; Ghelardini, C.; Mura, P. Development and characterization of niosomal formulations of doxorubicin aimed at brain targeting. J. Pharm. Pharm. Sci. 2012, 15, 184-196. https://doi.org/10.18433/J3230M PMid:22365096
28) Pando, D.; Matos, M.; Gutiérrez, G.; Pazos, C. Formulation of resveratrol entrapped niosomes for topical use. Colloids Surf. B Biointerfaces 2015, 128, 398-404. https://doi.org/10.1016/j.colsurfb.2015.02.037 PMid:25766923
29) Chowdhury, P.; Uma Shankar, M.S. Formulation and evaluation of Rifampicin and Ofloxacin niosomes for Drug-resistant TB on Logarithmic-phase cultures of Mycobacterium tuberculosis. Int. J. Rev. Life Sci. 2016, 3, 628-633.
30) Amiri, B.; Ahmadvand, H.; Farhadi, A.; Najmafshar, A.; Chiani, M.; Norouzian, D. Delivery of vinblastine-containing niosomes results in potent in vitro/in vivo cytotoxicity on tumor cells. Drug Dev. Ind. Pharm. 2018, 44, 1371-1376. https://doi.org/10.1080/03639045.2018.1451880 PMid:29532687
31) Pham, T.T.; Jaafar-Maalej, C.; Charcosset, C.; Fessi, H. Liposome and niosome preparation using a membrane contactor for scale-up. Colloids Surf. B Biointerfaces 2012, 94, 15-21. https://doi.org/10.1016/j.colsurfb.2011.12.036 PMid:22326648
32) Alsarra, I.A.; Bosela, A.A.; Ahmed, S.M.; Mahrous, G.M. Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur. J. Pharm. Bio pharm. 2005, 59, 485-490. https://doi.org/10.1016/j.ejpb.2004.09.006 PMid:15760729
33) Changsan N, Chan HK, Separovic F, Srichana T. Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation. J Pharm Sci. 2009;98(2):628-39. https://doi.org/10.1002/jps.21441 PMid:18484099
34) Manca ML, Sinico C, Maccioni AM, Diez O, Fadda AM, Manconi M. Composition influence on pulmonary delivery of rifampicin liposomes. Pharmaceutics. 2012;4(4):590-606. https://doi.org/10.3390/pharmaceutics4040590 PMid:24300372 PMCid:PMC3834926
35) Chimote G, Banerjee R .In vitro evaluation of inhalable isoniazid-loaded surfactant liposomes as an adjunct therapy in pulmonary tuberculosis .J Biomed Mater Res B Appl Biomater. 2010;94(1):1-10. https://doi.org/10.1002/jbm.b.31608 PMid:20524179
36) Booysen LL, Colombo L, Brooks E, Hansen R, Gilliland J, Gruppo V, et al.In vivo/in vitro pharmacokinetic and pharmacodynamics study of spray-dried poly-(dl-lactic-co-glycolic) acid nanoparticles encapsulating rifampicin and isoniazid. Int J Pharm. 2013;444(1-2):10-7. https://doi.org/10.1016/j.ijpharm.2013.01.038 PMid:23357255
37) Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Ear J Pharm Sci. 2003;18(2):113-20. https://doi.org/10.1016/S0928-0987(02)00251-8 PMid:12594003
38) Pooja D, Tunki L, Kulhari H, Reddy BB, Sistla R. Characterization, biorecognitive activity and stability of WGA grafted lipid nanostructures for the controlled delivery of rifampicin. Chem Phys Lipids. 2015;193:11-7. https://doi.org/10.1016/j.chemphyslip.2015.09.008 PMid:26409629
39) Singh H, Bhandari R, Kaur IP. Encapsulation of rifampicin in a solid lipid Nano particulate system to limit its degradation and interaction with isoniazid at acidic pH.Int J Pharm. 2013;446(1-2): 106-11. https://doi.org/10.1016/j.ijpharm.2013.02.012 PMid:23410991
40) Singh H, Jindal S. Singh, Sharma G, Kaur IP. Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety. Int J Pharm. 2015;485(1-2):138-51. https://doi.org/10.1016/j.ijpharm.2015.02.050 PMid:25769294
41) Rajera R, Nagpal K, Singh SK, Mishra DN. Niosomes: a controlled and novel drug delivery system. Biological and Pharmaceutical Bulletin. 2011 Jul 1;34(7):945-53. https://doi.org/10.1248/bpb.34.945 PMid:21719996
42) Yoshida H, Lehr CM, Kok W, Junginger HE, Verhoef JC, Bouwstra JA. Niosomes for oral delivery of peptide drugs. Journal of controlled release. 1992 Jul 1;21(1-3):145-53. https://doi.org/10.1016/0168-3659(92)90016-K
43) Moazeni E, Gilani K, Sotoudegan F, Pardakhty A, Najafabadi AR, Ghalandari R, Fazeli MR, Jamalifar H. Formulation and in vitro evaluation of ciprofloxacin containing niosomes for pulmonary delivery. Journal of microencapsulation. 2010 Nov 1;27(7):618-27. https://doi.org/10.3109/02652048.2010.506579 PMid:20681747 44)
44) VARMA JR, REDDY MK, KUMAR CP, REDDY AK, RAJU PP. Indian Journal of Novel Drug Delivery. Indian Journal of Novel Drug delivery. 2011 Oct;3(4):238-46.
45) Pardakhty A, Moazeni E. Nano-niosomes in drug, vaccine and gene delivery: a rapid overview. Nanomedicine Journal. 2013;1(1):1-2.
46) Rajera R, Nagpal K, Singh SK, Mishra DN. Niosomes: a controlled and novel drug delivery system. Biological and Pharmaceutical Bulletin. 2011 Jul 1;34(7):945-53. https://doi.org/10.1248/bpb.34.945 PMid:21719996
47) Kaur IP, Rana C, Singh M, Bhushan S, Singh H, Kakkar S. Development and evaluation of novel surfactant-based elastic vesicular system for ocular delivery of fluconazole. Journal of ocular pharmacology and therapeutics. 2012 Oct 1;28(5):484-96. https://doi.org/10.1089/jop.2011.0176 PMid:22694593
48) Siew A, Le H, Thiovolet M, Gellert P, Schatzlein A, Uchegbu I. Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles. Molecular pharmaceutics. 2012 Jan 1;9(1):14-28. https://doi.org/10.1021/mp200469a PMid:22047066
49) Azmin MN, Florence AT, Handjani-Vila RM, Stuart JF, Vanlerberghe G, Whittaker JS. The effect of niosomes and polysorbate 80 on the metabolism and excretion of methotrexate in the mouse. Journal of microencapsulation. 1986 Jan 1;3(2):95-100. https://doi.org/10.3109/02652048609031563 PMid:3508183
50) Rajera R, Nagpal K, Singh SK, Mishra DN. Niosomes: a controlled and novel drug delivery system. Biological and Pharmaceutical Bulletin. 2011 Jul 1;34(7):945-53. https://doi.org/10.1248/bpb.34.945 PMid:21719996
51) Pardakhty A, Varshosaz J, Rouholamini A. In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. International journal of pharmaceutics. 2007 Jan 10;328(2):130-41 53. Anna, M. https://doi.org/10.1016/j.ijpharm.2006.08.002 PMid:16997517
52) Katharina, L. Polymer micro- and nanocapsules as biological carriers with multifunctional properties. Macromol. Biosci. 2014, 14, 458-477. https://doi.org/10.1002/mabi.201300551 PMid:24616298
53) Rinaldi, F.; Hanieh, P.N.; Chan, L.K.N. Chitosan Glutamate-Coated Niosomes A Proposal for Nose-to-Brain Delivery. Pharmaceutics 2018, 10, 38. https://doi.org/10.3390/pharmaceutics10020038 PMid:29565809 PMCid:PMC6027090
54) Tangri, P.; Khurana, S. Niosomes: Formulation and evaluation. Int. J. Biopharm. 2011, 2, 47-53.
55) Shi, B.; Fang, C.; Pei, Y. Stealth PEG-PHDCA niosomes: effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity. J. Pharm. Sci. 2006, 95, 1873-1887. https://doi.org/10.1002/jps.20491 PMid:16795003
56) Dan, N. Chapter 2-Core-shell drug carriers: Liposomes, polymersomes, and niosomes. Nanostructure. Drug Deliv. 2017, 63-105. https://doi.org/10.1016/B978-0-323-46143-6.00002-6
57) Celia, C.; Trapasso, E.; Cosco, D.; Paolino, D.; Fresta, M. Turbiscan lab expert analysis of the stability of twosomes and ultra deformable liposomes containing a bilayer fluidizing agent. Colloids Surf. B Biointerfaces 2009, 72, 155-160. https://doi.org/10.1016/j.colsurfb.2009.03.007 PMid:19376689
58) Mahale, N.B.; Thakkar, P.D.; Mali, R.G.; Walunj, D.R.; Chaudhari, S.R. Niosomes: Novel sustained release Nonionic stable vesicular systems -An overview. Adv. Colloid Interface Sci. 2012, 183-184, 46-54. https://doi.org/10.1016/j.cis.2012.08.002 PMid:22947187
59) Junyaprasert, V.B.; Singhsa, P.; Jintapattanakit, A. Influence of chemical penetration enhancers on skin permeability of ellagic acid-loaded niosomes. Asian J. Pharm. Sci. 2013, 8, 110-117. https://doi.org/10.1016/j.ajps.2013.07.014
60) Sarthak, M.; Chiranjib, B.; Surajit, G.; Jagannath, K.; Nilmoni, S. Modulation of the photophysical properties of curcumin in nonionic surfactant (Tween-20) forming micelles and niosomes: A comparative study of different microenvironments. J. Phys. Chem. B 2013, 117, 6957. https://doi.org/10.1021/jp403724g PMid:23682632
61) Jiradej, M.; Narinthorn, K.; Worapaka, M.; Friedrich, G.T.; Werner, R.G.; Aranya, M. Enhancement of transdermal absorption, gene expression and stability of tyrosinase plasmid (pMEL34)-loaded elastic cationic niosomes: Potential application in vitiligo treatment. J. Pharm. Sci. 2010, 99, 3533-3541. https://doi.org/10.1002/jps.22104 Mid:20213835
62) Attia, N.; Mashal, M.; Grijalvo, S.; Eritja, R.; Zárate, J.; Puras, G.; Pedraz, J.L. Stem cell-based gene delivery mediated by cationic niosomes for bone regeneration. Nanomed. Nanotechnol. Biol. Med. 2017, 14, 521-531. https://doi.org/10.1016/j.nano.2017.11.005 PMid:29157978
63) Dufes, C.; Gaillard, F.; Uchegbu, I.F.; Schätzlein, A.G.; Olivier, J.C.; Muller, J.M. Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain. Int. J. Pharm. 2004, 285, 77-85. https://doi.org/10.1016/j.ijpharm.2004.07.020 PMid:15488681
64) Wilkhu, J. Non-Ionic Surfactant Technology for the Delivery and Administration of Sub-Unit Flu Antigens.Ph.D. Thesis, Aston University, Birmingham, UK, 2013.
65) Rentel, C.O.; Bouwstra, J.A.; Naisbett, B.; Junginger, H.E. Niosomes as a novel peroral vaccine delivery system. Int. J. Pharm. 1999, 186, 161-167. https://doi.org/10.1016/S0378-5173(99)00167-2 PMid:10486434
66) Taymouri, S.; Varshosaz, J. Effect of different types of surfactants on the physical properties and stability of carvedilol nano-niosomes. Adv. Biomed. Res. 2016, 5, 48. https://doi.org/10.4103/2277-9175.178781 PMid:27110545 PMCid:PMC4817389
67) Wang, J.; Sui, M.; Fan, W. Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr. Drug Metab. 2010, 11, 129-141. https://doi.org/10.2174/138920010791110827 PMid:20359289
68) . Salem, H.F.; Kharshoum, R.M.; Elela, F.I.A.; Amr, G.F.; Abdellatif, K.R.A. Evaluation and optimization of pH-responsive niosomes as a carrier for efficient treatment of breast cancer. Drug Deliv. Transl. Res. 2018, 8,633-644. https://doi.org/10.1007/s13346-018-0499-3 PMid:29488171
69) Juliano, R.L. Micro-particulateDrug Carriers. In Directed Drug Delivery; Springer Nature: Basel, Switzerland, 1985. https://doi.org/10.1007/978-1-4612-5186-6_9
70) Shilpa, S.; Srinivasan, B.P.; Chauhan, M. Niosomes as vesicular carriers for delivery of proteins and biologicals. Int. J. Drug Deliv. 2011, 3, 14-24. https://doi.org/10.5138/ijdd.2010.0975.0215.03050
71) Khaksa, G.; D'Souza, R.; Lewis, S.; Udupa, N. Pharmacokinetic study of niosome encapsulated insulin. Indian J. Exp. Biol. 2000, 38, 901.
72) Ning, M.; Guo, Y.; Pan, H.; Yu, H.; Gu, Z. Niosomes with sorbitan monoester as a carrier for vaginal delivery of insulin: Studies in rats. Drug Deliv. 2005, 12, 399-407. https://doi.org/10.1080/10717540590968891 PMid:16253956
73) Pardakhty, A.; Moazeni, E.; Varshosaz, J.; Hajhashemi, V.A.; Najafabadi, A.R. Pharmacokinetic study of niosome-loaded insulin in diabetic rats. Daru J. Pharm. Sci. 2011, 19, 404-411.
74) Yoshida, H.; Lehr, C.M.; Kok, W.; Junginger, H.E.; Verhoef, J.C.; Bouwstra, J.A. Niosomes for oral delivery of peptide drugs. J. Control. Release 1992, 21, 145-153. https://doi.org/10.1016/0168-3659(92)90016-K
75) Yvonne, P.; Mohammed, A.R.; Kirby, D.J.; Mcneil, S.E.; Bramwell, V.W. Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens. Int. J. Pharm. 2000, 364, 272-280. https://doi.org/10.1016/j.ijpharm.2008.04.036 PMid:18555624
76) Mahato, R.I.; Rolland, A.; Tomlinson, E. Cationic Lipid-Based Gene Delivery Systems: Pharmaceutical Perspectives. Pharm. Res. 1997, 14, 853-859. https://doi.org/10.1023/A:1012187414126 PMid:9244140
77) Mintzer, M.A.; Simanek, E.E. Nonviral Vectors for Gene Delivery. Chem. Rev. 2009, 109, 259-302. https://doi.org/10.1021/cr800409e PMid:19053809
78) Jain, S. Non-ionic surfactant based vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis B. Int. J. Pharm. 2005, 296, 80-86. https://doi.org/10.1016/j.ijpharm.2005.02.016 PMid:15885458
79) Yang, C.; Gao, S.; Song, P.; Dagnaes-Hansen, F.; Jakobsen, M.; Kjems, J. Theranostic Niosomes for Efficient siRNA/microRNA Delivery and Activatable Near-Infrared Fluorescent Tracking of Stem Cells. Acs Appl. Mater. Interfaces 2018, 10, 19494-19503. https://doi.org/10.1021/acsami.8b05513 PMid:29767944
80) Mayr, J.; Grijalvo, S.; Bachl, J.; Pons, R.; Eritja, R.; Díaz, D.D. Transfection of Antisense Oligonucleotides Mediated by Cationic Vesicles Based on Non-Ionic Surfactant and Polycations Bearing Quaternary Ammonium Moieties. Int. J. Mol. Sci. 2017, 18, 1139. https://doi.org/10.3390/ijms18061139 PMid:28587106 PMCid:PMC5485963
81) Hume, L.R. A Comparative Study of Niosomes (Non-Ionic Surfactant Vesicles) and Liposomes: Their Stability in Biological Environments. Doctoral Dissertation, University of Strathclyde, Glasgow, Scotland, 1987.
82) Rogerson, A.; Cummings, J.; Willmott, N.; Florence, A.T. The distribution of doxorubicin in mice following administration in niosomes. J. Pharm. Pharm. 2011, 40, 337-342. https://doi.org/10.1111/j.2042-7158.1988.tb05263.x PMid:2899629
83) Uchegbu, I.F.; Double, J.A.; Turton, J.A.; Florence, A.T. Distribution, Metabolism and Tumoricidal Activity of Doxorubicin Administered in Sorbitan Monostearate (Span 60) Niosomes in the Mouse. Pharm. Res. 1995, 12, 1019-1024. https://doi.org/10.1023/A:1016210515134 PMid:7494796
84) Azmin, M.N.; Florence, A.T.; Handjani-Vila, R.M.; Stuart, J.F.; Vanlerberghe, G.; Whittaker, J.S. The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J. Pharm. Pharm. 2011, 37, 237-242. https://doi.org/10.1111/j.2042-7158.1985.tb05051.x PMid:2860220
85) Ke, P.C.; Lin, S.; Parak, W.J.; Davis, T.P.; Caruso, F. A Decade of the Protein Corona. Acs Nano 2017, 11, 11773-11776. https://doi.org/10.1021/acsnano.7b08008 PMid:29206030
86) Daniele, M.; Paolo, B.; Eugene, M.; Dawson, K.A.; Monopoli, M.P. Surfactant titration of nanoparticle-protein corona. Anal. Chem. 2014, 86, 12055-12063. https://doi.org/10.1021/ac5027176 PMid:25350777
87) Marilena, H.; Zahraa, A.A.; Mariarosa, M.; Collins, R.F.; Kenneth, D.; Kostas, K. In Vivo Biomolecule Corona around Blood-Circulating, Clinically Used and Antibody-Targeted Lipid Bilayer Nanoscale Vesicles. ACS Nano 2015, 9, 8142-8156. https://doi.org/10.1021/acsnano.5b03300 PMid:26135229
88) Tommy, C.; Iseult, L.; Stina, L.; Tord, B.R.; Eva, T.; Hanna, N.; Dawson, K.A.; Sara, L. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl. Acad. Sci. USA 2007, 104, 2050-2055. https://doi.org/10.1073/pnas.0608582104 PMid:17267609 PMCid:PMC1892985
Crossmark
Statistics
157 Views | 6 Downloads
How to Cite
1.
Shanker O, Chanana A, Gupta P, Narayan A, Kulkarni YR, Patel A, havelikar U, Mahato B, Singh RP, Chawra HS, Mishra A. Niosomal Drug Delivery System used in Tuberculosis. JDDT [Internet]. 15Mar.2024 [cited 19Apr.2024];14(3):218-26. Available from: https://jddtonline.info/index.php/jddt/article/view/6475